anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a preparation method of traditional Chinese medicine wine capable of improving eyesight and solidifying marrows. The wine is prepared from 100ml of wolfberry fruit juice, 100ml of radix rehmanniae juice, 60ml of Liriope spicata juice, 30ml of almond soup (without tips), 20g of ginseng, 30g of white tuckahoe and 100ml of white wine. The preparation method comprises the following steps: pouring the first 6 medicinal juices (soup) into white wine, evenly mixing, sealing, immersing for 15 days, and filtering to remove slag. The wine has the effects of replenishing vital essence, solidifying marrows, nourishing yin, improving eyesight, moisturizing the viscera and prolonging life. The wine is mainly used for treating deficiency of the kidney and essence, asthenia, impotence, inappetence, deafness and blurring of vision, pale face, haggardness, coarse skin, constipation and other symptoms. The wine is orally taken 10-15ml a time and twice a day.
The invention discloses a traditional Chinese medicine for treating chicken intestinal ulcer. The traditional Chinese medicine is characterized in that the formula comprises the following ingredients in parts by weight: 4-5 parts of bletilla striata, 4-5 parts of radix paeoniae alba, 4-5 parts of angelica sinensis, 3-4 parts of radix bupleuri, 3-4 parts of tuckahoe, 3-4 parts of rhizoma cyperi, 4-5 parts of semen plantaginis, 4-5 parts of hemp palm carbon, 4-5 parts of scutellaria baicalensis, 3-4 parts of white atractylodes rhizome, 4-5 parts of corydalis tuber, 2-3 parts of platycodon grandiflorum, 4-5 parts of moutan bark, and 2-3 parts of liquorice. According to the formula, the traditional Chinese medicine has the functions of relieving liver and smoothing qi, nourishing blood and liver, tonifying spleen and dehumidifying to effect a permanent cure, and has the functions of removing fire and helping digestion, scattering stasis and stopping blood, smoothing liver and stomach, and removing the necrotic tissue and promoting tissue regeneration to take temporary solution. The principle of treating both symptoms and root causes is adopted. The traditional Chinese medicine composition disclosed by the invention is prepared from 14 traditional Chinese medicinal materials; the raw materials are easily available and are low in cost, so the traditional Chinese medicine is economic and applicable. The formula is based on the principle of treating both symptoms and root causes and meets the treatment requirements of the Chicken intestinal ulcer at different onset outbreak stages.
Chimeric antigen receptor (CAR)-modified T cells targeted against CD19 have demonstrated unprecedented successes in treating patients with hematopoietic and lymphoid malignancies. Besides CD19, many other molecules such as CD22, CD30,BCMA,CD123, etc. may have the potential to develop the corresponding CAR-T cells to treat patients whose tumors express those markers. In this study, investigators will evaluate the safety and efficacy of CAR-T targeting CD19/BCMA in patients with Autoimmune Disease. The primary goal is safety assessment including cytokine storm response and any other adverse effects. In addition, disease status after treatment will also be evaluated.

The purpose of this clinical trial is to assess the feasibility, safety, and efficacy of multiple CAR T-cell therapy that combines CAR T cells against Autoimmune Disease B Cells with CAR T cells targeting BCMA or CD19 or both in patients with relapsed and refractory Autoimmune Disease. The study also aims to learn more about the function of CAR T cells and their persistence in Autoimmune Disease patients.
The proposed study will be a randomized, crossover design in which experimental pain will be induced in healthy subjects using hypertonic saline injections to three muscles of the lower extremities: The gastrocnemius muscle, the vastus medialis muscle, and the semitendinosus muscle. Participants will be block-randomized to receive an injection in each of the three muscles and will receive either the painful or control condition first for each muscle. The participant will always be blinded to the type of injection received.

Following the injection, there will typically be a 15-minute window of pain (45). Within this timeframe, motion capture will be carried out for both the control and painful conditions. During motion capture, the participants will perform multiple walking trials of approximately 10 meters. The participants will be equipped with electromyography (EMG) sensors on key muscles of the lower extremities. The participants will be asked for NRS ratings every 30 seconds throughout the 15 minutes with expected pain. There will be a 15-minute washout between the muscle injections.
PURPOSE: The primary objective was to validate the construct validity of the Japanese Core Outcome Measures Index (COMI) in preoperative patients aged 60 years or older undergoing lumbar spine surgery for lumbar spinal stenosis (LSS) and lumbar disk herniation (LDH). Additionally, as a secondary aim, we explored the impact of these diseases on quality of life (QOL).
METHODS: The analysis included 199 preoperative patients aged 60 and above who were scheduled for lumbar spine surgery. To assess QOL, Japanese versions of the COMI, Oswestry Disability Index (ODI), EuroQol-5 Dimension-3 Level (EQ-5D-3L), and SF-12v2 were employed. The study assessed the validity of the COMI and compared demographic and clinical characteristics between the LSS (147 cases) and LDH (52 cases) groups. It used multivariate covariance analysis (MANCOVA) to examine the impact of diseases (LSS and LDH) on each patient-reported outcome measure while considering covariates.
RESULTS: Compared to the LSS group, the LDH group showed more difficulty with the COMI summary score (LSS/LDH [mean]: 6.9/8.1, p < 0.001), ODI score (46.8/57.4, p < 0.001), and EQ-5D utility (0.53/0.43, p < 0.001). The LDH group also reported more difficulties in the COMI-function, COMI-symptom-specific well-being, COMI-disability, ODI-personal care, ODI-social life, and SF-12v2-bodily pain subscales. MANCOVA demonstrated that these results were not influenced by covariates such as gender and medical history.
CONCLUSIONS: This study highlights the distinct impact of LSS and LDH on preoperative QOL in older patients undergoing lumbar spinal surgery. Tailored interventions are essential to address the specific challenges posed by these conditions and improve patient-centered outcomes and postoperative recovery.
This is a phase I, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to assess the safety, tolerability, and pharmacokinetics of HS-10356 oral formulation in Chinese healthy adult volunteers.

Approximately five sequential dose panels (single oral doses of 2,6,15,30,45mg HS-10356) will be evaluated in SAD. To protect the safety of volunteers, two sentinel volunteers were first enrolled in the first dose panel (2mg panel) and randomly assigned to HS-10356 or placebo in a 1:1 ratio. After the sentinel volunteers were given the dose for at least 24 hours and confirmed that they were safe, the remaining 6 volunteers were randomly assigned to HS-10356 or placebo in a ratio of 5:1. For the follow-up panels of SAD, volunteers were randomly assigned to either the experimental group or the placebo group (6 cases in HS-10356 and 2 cases in placebo) in a 3:1 ratio using block randomization method. Approximately three sequential dose panels (14 consecutive days for respectively daily oral doses of 6,15,30mg HS-10356, QD) will be evaluated in MAD. Volunteers were randomly assigned to either the experimental group or the placebo group (9 cases in the HS-10356 and 3 cases in the placebo) in a ratio of 3:1 using block randomization method. Each subject will receive only one regimen in this study. Safety data up to Day12 (±2) in SAD and up to Day25 (±2) in MAD will be reviewed prior to dose escalation. Cohorts of SAD and MAD will be added or removed depending on the assessment results of SRC.
Participants will receive escalating doses of XmAb24306 with a fixed dose regimen for cevostamab up to the maximum tolerated dose (MTD). After dose escalation has been completed, up to two expansion cohorts each investigating different XmAb24306 doses in combination with cevostamab may be enrolled.
PROBLEM TO BE SOLVED: To obtain a perfumery composition free from selectivity in perfumery note, having excellent effect to improve the fondness for the flavor and keeping the effect over a long period by using hexadecanoic acid as a component. SOLUTION: This perfumery composition contains preferably 0.00001-90wt.% (based on the total perfumery composition) of hexadecanoic acid. Hexadecanoic acid is preferably produced e.g. by extracting the human skin secretion secreted from the sebaceous gland or extracting and separating from vegetable oil and fat. Hexadecanoic acid is preferably combined with civetone, (-)-muscone, androstenol or 3-methyl-2-hexenoic acid to enable the arrangement of the characteristic flavor of these compounds to a mild fragrance and get a perfumery composition with unlimited variation. The amounts of civetone, (-)-muscone, androstenol and 3-methyl-2-hexenoic acid are preferably 10-100 pts. wt., 1-100 pts.wt., 0.02-2 pts. wt. and 0.0002-0.02 pts.wt. based on 100 pts.wt. of hexadecanoic acid, respectively.
The invention provides fluorescence-labeled pyrazine compounds for beta-amyloid plaques and neurofibrillary tangles. The general structural formula of the compounds is as shown in a formula (I) or a formula (II) which is described in the specification. In the formula, n is 1, 2 or 3. The invention also provides a preparation method and application of the compounds. The compounds can be directly used as a developer for detecting or developing beta-amyloid plaques or neurofibrillary tangles in the tissue of animal or human bodies. The compounds are especially applicable to preparation of developers or diagnosis medicines used for direct detection and diagnosis of beta-amyloid deposit diseases or neurofibrillary tangle diseases including the Alzheimer disease.
Neurofibromatosis Type 2 (NF2) is characterized by multiple tumors of the cranial and spinal nerves, and, in particular, by bilateral acoustic tumors. Surgical resection of these tumors generally results in the transection of the VIIIth nerve, destruction of the cochlea and auditory nerve, and total hearing loss. Due to the loss of the auditory nerve, these patients are not candidates for cochlear implantation. The Auditory Brainstem Implant (ABI) provides the only available intervention to restore some auditory sensation to these patients. An ABI is an implantable prosthesis that produces sound sensation by electrical stimulation of the ascending auditory pathway at the level of the cochlear nucleus.

The PABI may be placed surgically during tumor resection. Efficacy will be assessed using psychophysical and standard speech reception measures.
Cholesterol is probably the sole precursor of bile acids. During normal digestion, bile acids are secreted into the intestines. A major portion of the bile acids is absorbed from the intestinal tract and returned to the liver via the enterohepatic circulation. Only very small amounts of bile acids are found in normal serum.

Cholestyramine resin adsorbs and combines with the bile acids in the intestine to form an insoluble complex which is excreted in the feces. This results in a partial removal of bile acids from the enterohepatic circulation by preventing their absorption.

The increased fecal loss of bile acids due to cholestyramine resin administration leads to an increased oxidation of cholesterol to bile acids, a decrease in beta lipoprotein or low-density lipoprotein plasma levels and a decrease in serum cholesterol levels. Although in man, cholestyramine resin produces an increase in hepatic synthesis of cholesterol, plasma cholesterol levels fall.

In patients with partial biliary obstruction, the reduction of serum bile acid levels by cholestyramine resin reduces excess bile acids deposited in the dermal tissue with resultant decrease in pruritus.
The intestinal epithelium fulfills important physiological functions and forms a physical barrier to the intestinal lumen. Barrier function is regulated by several pathways, and its impairment contributes to the pathogenesis of inflammatory bowel disease (IBD), a chronic inflammatory condition affecting more than seven million people worldwide. Current treatment options specifically target inflammatory mediators and have led to improvement of clinical outcomes; however, a significant proportion of patients experience treatment failure. Pro-repair effects of inflammatory mediators on the epithelium are emerging. In this review we summarize current knowledge on involved epithelial pathways, identify open questions, and put recent findings into clinical perspective, and pro-repair effects. A detailed understanding of epithelial pathways integrating mucosal stimuli in homeostasis and inflammation is crucial for the development of novel, more targeted therapies.
FIELD: medicine, phytotherapy. SUBSTANCE: invention proposes species of medicinal plants by hypertonic type comprising haw-thorn fruits, wild rose fruits, common wormwood herb, Saint-John's-wort herb, wild strawberry leaves, mint leaves, birch buds, valerian rhizomes with roots, motherwort herb, swampy cudweed herb, hop compound fruits and maize styles with stigmas taken in the equal ratio. Invention proposes also species of medicinal plants by hypotonic type comprising haw-thorn fruits, wild rose fruits, Saint-John's-wort herb, wild strawberry leaves, mint leaves, birch buds, licorice roots, major plantain leaves and knot-grass herb taken in the equal ratio. Proposed species allow to expand assortment of agents used in treatment of neurocirculatory dystonia of different direction of pharmacological effect. Invention can be used for treatment of patients with neurocirculatory dystonia. EFFECT: enhanced effectiveness of species and treatment. 2 cl, 2 dwg
A hairspray composition is described that includes a nonionic polymer and an anionic polymer. The nonionic polymer is formed from monomers having at least one unneutralized carboxylic acid. The anionic polymer is identical to the nonionic one, except that all of the carboxylic acid groups are in salt form. Advantageously, the composition further includes an acrylic resin, most especially an amphoteric one. Best results are achieved when the acrylic resin is neutralized with a relatively small cation such as potassium and a second cation of a water soluble fatty amine. These compositions employ water as the carrier and dimethyl ether as propellant.
AIMS: This review summarizes the findings of preclinical studies evaluating the pleiotropic effects of ticagrelor. These include attenuation of ischemia-reperfusion injury (IRI), inflammation, adverse cardiac remodeling, and atherosclerosis. In doing so, it aims to provide novel insights into ticagrelor's mechanisms and benefits over other P2Y12 inhibitors. It also generates viable hypotheses for the results of seminal clinical trials assessing ticagrelor use in acute and chronic coronary syndromes.
METHODS AND RESULTS: A comprehensive review of the preclinical literature demonstrates that ticagrelor protects against IRI in the setting of both an acute myocardial infarction (MI), and when MI occurs while on chronic treatment. Maintenance therapy with ticagrelor also likely mitigates adverse inflammation, cardiac remodeling, and atherosclerosis, while improving stem cell recruitment. These effects are probably mediated by ticagrelor's ability to increase local interstitial adenosine levels which activate downstream cardio-protective molecules. Attenuation and augmentation of these pleiotropic effects by high-dose aspirin and caffeine, and statins respectively may help explain variable outcomes in PLATO and subsequent randomized controlled trials (RCTs).
CONCLUSION: Most RCTs and meta-analyses have not evaluated the pleiotropic effects of ticagrelor. We need further studies comparing cardiovascular outcomes in patients treated with ticagrelor versus other P2Y12 inhibitors that are mindful of the unique pleiotropic advantages afforded by ticagrelor, as well as possible interactions with other therapies (e.g., aspirin, statins, caffeine).
The invention discloses a make-up color containing structural color chips and a preparation method thereof. The method specifically comprises the following steps: (1) PSMA (polystyrene-co-maleic anhydride) colloidal microspheres were prepared by a conventional emulsion polymerization method. (2) After amination of the core layer PSMA microsphere by Polyethyleneimine (PEI), preparing the organic-inorganic core-shell microsphere (PSMA@Au, PSMA@Ag) with higher surface charge density by adopting an in-situ reduction method. (3) The PSMA@Au core-shell microspheres are used as construction elements, and a heating convection self-assembly method is adopted to construct the photonic crystal. (4) The prepared photonic crystal film enhances the dispersibility of the color chip by grinding the color chip and coating a surfactant (sodium dodecyl sulfate) on the surface of the photonic crystal film. The invention prepares the multifunctional structural color chip with high efficiency, broad spectrum, long-acting antibacterial property, ultraviolet resistance, nano-level particle size, controllable color and the like through structural and functional design, can prepare metamaterial high-end eye shadow and lip gloss, and improves the quality of cosmetics for eyebrows, eyes and lips.
This is a phase II study to assess the safety and efficacy of the combination of nivolumab with ipilimumab and cabozantinib in patients with untreated brain metastases from RCC until disease progression or intolerable toxicities or patient withdrawal. We will accrue a total of 40 patients. Patients will be treated with nivolumab (3mg/kg) and ipilimumab (1mg/kg) IV every 3 weeks for 4 doses and cabozantinib 40mg daily. Then patients will be treated with nivolumab 480mg IV Q 4 weeks and cabozantinib 40mg daily until progression or intolerable toxicities or patient's withdrawal. A lead-in group of 6 patients will be closely monitored for DLT. If stopping criteria (\>3 patients develop DLTs) is met then, treatment will be switched to Nivolumab plus Cabozantinib omitting ipilimumab.
Participants will receive 5.6 mg/kg U3-1402 intravenously on day 1 every 3 weeks. Part B will enroll 20 participants with metastatic hormone-receptor positive (HR+) HER2-negative cancer and 20 participants with metastatic triple-negative breast cancer (mTNBC), regardless of HER3 expression.
Propranolol is a nonselective, beta-adrenergic receptor-blocking agent possessing no other autonomic nervous system activity. It specifically competes with beta-adrenergic receptor-stimulating agents for available receptor sites. When access to beta-receptor sites is blocked by propranolol, the chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation are decreased proportionately. At dosages greater than required for beta blockade, propranolol also exerts a quinidine-like or anesthetic-like membrane action, which affects the cardiac action potential. The significance of the membrane action in the treatment of arrhythmias is uncertain.

Inderal LA should not be considered a simple mg-for-mg substitute for conventional propranolol and the blood levels achieved do not match (are lower than) those of two to four times daily dosing with the same dose (see DOSAGE AND ADMINISTRATION). When changing to Inderal LA from conventional propranolol, a possible need for retitration upwards should be considered, especially to maintain effectiveness at the end of the dosing interval. In most clinical settings, however, such as hypertension or angina where there is little correlation between plasma levels and clinical effect, Inderal LA has been therapeutically equivalent to the same mg dose of conventional Inderal as assessed by 24-hour effects on blood pressure and on 24-hour exercise responses of heart rate, systolic pressure, and rate pressure product.
Atrial fibrillation (AF) is an extremely common clinical arrhythmia disease, but whether its mechanism is associated with ferroptosis remains unclear. The tRNA-derived small RNAs (tsRNAs) are involved in a variety of cardiovascular diseases, however, their role and mechanism in atrial remodeling in AF have not been studied. We aimed to explore whether tsRNAs mediate ferroptosis in AF progression. The AF models were constructed to detect ferroptosis-related indicators, and Ferrostatin-1 (Fer-1) was introduced to clarify the relationship between ferroptosis and AF. Atrial myocardial tissue was used for small RNA sequencing to screen potential tsRNAs. tsRNA functioned on ferroptosis and AF was explored. Atrial fibrosis and changes in the cellular structures and arrangement were observed in AF mice model, and these alterations were accompanied by ferroptosis occurrence, exhibited by the accumulation of Fe2+ and MDA levels and the decrease of expression of FTH1, GPX4, and SLC7A11. Blocking above ferroptosis activation with Fer-1 resulted in a significant improvement for AF. A total of 7 tsRNAs were upregulated (including tsRNA-5008a) and 2 tsRNAs were downregulated in atrial myocardial tissue in the AF group compared with the sham group. We constructed a tsRNA-mRNA regulated network, which showed tsRNA-5008a targeted 16 ferroptosis-related genes. Knockdown of tsRNA-5008a significantly suppressed ferroptosis through targeting SLC7A11 and diminished myocardial fibrosis both in vitro and in vivo. On the contrary, tsRNA-5008a mimics promoted ferroptosis in cardiomyocytes. Collectively, tsRNA-5008a involved in AF through ferroptosis. Our study provides novel insights into the role of tsRNA-5008a mediated ferroptosis in AF progression.
Participants participate in stretching exercise sessions over 90 minutes for 4 sessions either once weekly or every 3 weeks. Participants also wear actigraph activity monitor and complete a sleep diary for 7 days. Participants receive instructional yoga audiotape and printed instructions to use at home upon completion of sessions. Participants have the option to attend Tibetan yoga sessions upon completion of 12-month follow-up.
Mental illnesses are one of the biggest contributors to the global disease burden. Despite the increased recognition, diagnosis and ongoing research of mental health disorders, the etiology and underlying molecular mechanisms of these disorders are yet to be fully elucidated. Moreover, despite many treatment options available, a large subset of the psychiatric patient population is nonresponsive to standard medications and therapies. There has not been a comprehensive study to date examining the burden and impact of treatable genetic disorders (TGDs) that can present with neuropsychiatric features in psychiatric patient populations. In this study, we test the hypothesis that TGDs that present with psychiatric symptoms are more prevalent within psychiatric patient populations compared to the general population by performing targeted next-generation sequencing of 129 genes associated with 108 TGDs in a cohort of 2301 psychiatric patients. In total, 48 putative affected and 180 putative carriers for TGDs were identified, with known or likely pathogenic variants in 79 genes. Despite screening for only 108 genetic disorders, this study showed a two-fold (2.09%) enrichment for genetic disorders within the psychiatric population relative to the estimated 1% cumulative prevalence of all single gene disorders globally. This strongly suggests that the prevalence of these, and most likely all, genetic diseases is greatly underestimated in psychiatric populations. Increasing awareness and ensuring accurate diagnosis of TGDs will open new avenues to targeted treatment for a subset of psychiatric patients.